A prodrug form of C-82
Related Products
Active Metabolite(s)
42038C-82
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PRI-724

Item No. 41728

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(6S,9S,9aS)-hexahydro-2,9-dimethyl-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonooxy)phenyl]methyl]-8-(8-quinolinylmethyl)-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
CAS Number
1422253-38-0
Molecular Formula
C33H35N6O7P
Formula Weight
658.7
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble: ≥10 mg/ml
SMILES
[H][C@]1(N(C(NCC2=CC=CC=C2)=O)N(C)CC(N1[C@H]3CC4=CC=C(OP(O)(O)=O)C=C4)=O)[C@H](C)N(CC5=CC=CC6=C5N=CC=C6)C3=O
InChi Code
InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1
InChi Key
VHOZWHQPEJGPCC-AZXNYEMZSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $61

    Add

    10 mg

    $109

    Add

    25 mg

    $258

    Add

    50 mg

    $484

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    PRI-724 is a prodrug form of the β-catenin/CREB-binding protein (CBP) inhibitor C-82 and a derivative of ICG-001 (Item No. 16257).1 It is cytotoxic to GES-1 gastric mucosal and HGC-27, MKN45, and AGS gastric cancer cells (IC50s = 16.53, 9.8, 44.28, and 3.48 µM, respectively) and enhances decreases in viability induced by lonidamine (Item No. 14640) or 2-deoxy-D-glucose (2-DG; Item No. 14325) in CAL 27, SCC-25, and BICR 22 tongue squamous carcinoma cells.2,3 PRI-724 (0.4 mg/animal) reduces hepatic fibrosis in a mouse model of liver fibrosis induced by carbon tetrachloride (CCl4).1 It reduces the proliferation of CD4+ or CD8+ stem cell memory and central memory T cells in a rhesus macaque model of antiretroviral therapy-suppressed simian immunodeficiency virus (SIV) infection when administered at doses of 10 or 20 mg/kg per day.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Osawa, Y., Oboki, K., Imamura, J., et al. Inhibition of cyclic adenosine monophosphate (cAMP)-response element-binding protein (CREB)-binding protein (CBP)/β-catenin reduces liver fibrosis in mice. EBioMedicine 2(11), 1751-1758 (2015).

    2. Yu, Z., Jiang, X., Qin, L., et al. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene 40(5), 1027-1042 (2021).

    3. Kleszcz, R., and Paluszczak, J. The Wnt signaling pathway inhibitors improve the therapeutic activity of glycolysis modulators against tongue cancer cells. Int. J. Mol. Sci. 23(3), 1248 (2022).

    4. Mavigner, M., Zanoni, M., Tharp, G.K., et al. Pharmacological modulation of the Wnt/β-catenin pathway inhibits proliferation and promotes differentiation of long-lived memory CD4+ T cells in antiretroviral therapy-suppressed simian immunodeficiency virus-infected macaques. J. Virol. 94(1), e01094-01019 (2019).